172 related articles for article (PubMed ID: 12084189)
21. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
22. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
23. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
24. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
25. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
26. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer.
Stock RG; Stone NN; Iannuzzi C
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):267-72. PubMed ID: 8635932
[TBL] [Abstract][Full Text] [Related]
27. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
[TBL] [Abstract][Full Text] [Related]
28. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
29. Does brachytherapy have a role in the treatment of prostate cancer?
Grimm PD; Blasko JC; Ragde H; Sylvester J; Clarke D
Hematol Oncol Clin North Am; 1996 Jun; 10(3):653-73. PubMed ID: 8773503
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the relationship between prescribed dose and dosimetric advantage of real-time intraoperatively built custom-linked seeds in iodine-125 prostate brachytherapy.
Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
Radiat Oncol; 2017 Dec; 12(1):192. PubMed ID: 29191234
[TBL] [Abstract][Full Text] [Related]
31. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
Lawton CA; DeSilvio M; Lee WR; Gomella L; Grignon D; Gillin M; Morton G; Pisansky T; Sandler H
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):39-47. PubMed ID: 17084551
[TBL] [Abstract][Full Text] [Related]
32. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
[TBL] [Abstract][Full Text] [Related]
33. Probability of late rectal morbidity in 125I prostate brachytherapy.
Waterman FM; Dicker AP
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):342-53. PubMed ID: 12527047
[TBL] [Abstract][Full Text] [Related]
34. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
35. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
36. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Urology; 2002 Jul; 60(1):98-103. PubMed ID: 12100932
[TBL] [Abstract][Full Text] [Related]
37. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
Crook JM; Potters L; Stock RG; Zelefsky MJ
Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
[TBL] [Abstract][Full Text] [Related]
38. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
Seung SK; Kroll S; Wilder RB; Posner MD; Roach M
Cancer J Sci Am; 1998; 4(3):168-74. PubMed ID: 9612598
[TBL] [Abstract][Full Text] [Related]
39. Current issues in techniques of prostate brachytherapy.
Nori D; Moni J
Semin Surg Oncol; 1997; 13(6):444-53. PubMed ID: 9358592
[TBL] [Abstract][Full Text] [Related]
40. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
